Michael Leiss

Michael Leiss

Auto-generated profile, based on publicly available information

Michael Leiss

Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
TGTobias Graf
Tobias Graf
KHKatrin Heinrich
Katrin Heinrich
IGIngrid Grunert
Ingrid Grunert
HWHarald Wegele
Harald Wegele
MHMarkus Haberger
Markus Haberger
MLMichael Leiss
Michael Leiss

21 May 2024 in Journal of Chromatography A
Verified
Journal Article
Open access
TGTobias Graf
Tobias Graf
LNLukas Naumann
Lukas Naumann
LBLea Bonnington
Lea Bonnington
JHJakob Heckel
Jakob Heckel
BSBernhard Spensberger
Bernhard Spensberger
MLMichael Leiss
Michael Leiss
The application of Process Analytical Technology (PAT) principles for manufacturing of biotherapeutics proffers the prospect of ensuring consistent product quality along with increased productivity as well as substantial cost and time savings. Although this paradigm shift from a traditional, rather rigid manufacturing model to a more scientific, risk-based approach has been advocated by health authorities for almost two decades, the practical implementation of PAT in the biopharmaceutical industry is still limited by the lack of fit-for-purpose analytical methods. In this regard, most of the proposed spectroscopic techniques are sufficiently fast but exhibit deficiencies in terms of selectivity and sensitivity, while well-established offline methods, such as (ultra-)high-performance liquid chromatography, are generally considered as too slow for this task. To address these reservations, we introduce here a novel online Liquid Chromatography (LC) setup that was specifically designed to enable real-time monitoring of critical product quality attributes during time-sensitive purification operations in downstream processing. Using this online LC solution in combination with fast, purpose-built analytical methods, sampling cycle times between 1.30 and 2.35 min were achieved, without compromising on the ability to resolve and quantify the product variants of interest. The capabilities of our approach are ultimately assessed in three case studies, involving various biotherapeutic modalities, downstream processes and analytical chromatographic separation modes. Altogether, our results highlight the expansive opportunities of online LC based applications to serve as a PAT tool for biopharmaceutical manufacturing.

20 May 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
TGTobias Graf
Tobias Graf
KAKathrin Abstiens
Kathrin Abstiens
FWFrank Wedekind
Frank Wedekind
CECarsten Elger
Carsten Elger
MHMarkus Haindl
Markus Haindl
MLMichael Leiss
Michael Leiss

26 April 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
SGSanjay K. Gupta
Sanjay K. Gupta
TGTobias Graf
Tobias Graf
FEFranziska T. Edelmann
Franziska T. Edelmann
HSHelen Seelmann
Helen Seelmann
MRMarkus Reintinger
Markus Reintinger
MLMichael Leiss
Michael Leiss
Hydrolysis of polysorbate in biopharmaceutical products has been ascribed to the enzymatic activity from trace levels of residual host cell proteins. In recent years, significant efforts to identify the causative enzymes typically used elaborate, material-intensive and time-consuming approaches. Therefore, the lack of fast and sensitive assays to monitor their activity remains a major bottleneck for supporting process optimization and troubleshooting activities where time and sample throughput are crucial constraints. To address this bottleneck, we developed a novel Electrochemiluminescence-based Polysorbase Activity (EPA) assay to measure hydrolytic activities in biotherapeutics throughout the drug substance manufacturing process. By combining the favorable features of an in-house designed surrogate substrate with a well-established detection platform, the method yields fast (∼36 h turnaround time) and highly sensitive readouts compatible with high-throughput testing. The assay capability for detecting substrate conversion in a precise and reliable manner was demonstrated by extensive qualification studies and by employing a number of recombinant hydrolases associated with polysorbate hydrolysis. In addition, high assay sensitivity and wide applicability were confirmed for in-process pool samples of three different antibody products by performing a head-to-head comparison between this method and an established liquid chromatography - mass spectrometry based assay for the quantification of free fatty acids. Overall, our results suggest that this new approach is well-suited to resolve differences in hydrolytic activity through all stages of purification.

1 November 2023 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
JHJakob Heckel
Jakob Heckel
AMAndres Martinez
Andres Martinez
CECarsten Elger
Carsten Elger
MHMarkus Haindl
Markus Haindl
MLMichael Leiss
Michael Leiss
TGTobias Graf
Tobias Graf
Recombinant adeno-associated viruses (rAAVs) are promising gene delivery vectors in the emerging field of in vivo gene therapies. To ensure their consistent quality during manufacturing and process development, multiple analytical techniques have been proposed for the characterization and quantification of rAAV capsids. Despite their indisputable capabilities for performing this task, current analytical methods are rather time-consuming, material intensive, complicated, and costly, restricting their suitability for process development in which time and sample throughput are severe constraints. To eliminate this bottleneck, we introduce here an affinity-based high-performance liquid chromatography method that allows the determination of the capsid titer and the full/empty ratio of rAAVs within less than 5 min. By packing the commercially available AAVX affinity resin into small analytical columns, the rAAV fraction of diverse serotypes can be isolated from process-related impurities and analyzed by UV and fluorescence detection. As demonstrated by both method qualification data and side-by-side comparison with AAV enzyme-linked immunosorbent assay results for rAAV8 samples as well as by experiments using additional rAAV2, rAAV8, and rAAV9 constructs, our approach showed good performance, indicating its potential as a fast, simple and efficient tool for supporting the development of rAAV gene therapies.

12 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KHKatrin Heinrich
Katrin Heinrich
SHSina Hoelterhoff
Sina Hoelterhoff
SOSaban Oezipek
Saban Oezipek
MWMartin Georg Winter
Martin Georg Winter
TRTobias Rainer
Tobias Rainer
ABAnja Bathke
Anja Bathke
Background/Objectives: Multi-dimensional liquid chromatography coupled with mass spectrometry (mD-LC-MS) has emerged as a powerful technique for the in-depth characterization of biopharmaceuticals by assessing chromatographically resolved product variants in a streamlined and semi-automated manner. The study aims to demystify and enhance the accessibility to this powerful but inherently complex technique by detailing a robust and user-friendly instrument platform, allowing analysts to switch seamlessly between intact, subunit, and peptide mapping workflows. Methods: Starting from a commercially available Two-Dimensional Liquid Chromatography (2D-LC) system, we introduce specific hardware and software extensions leading to two versatile mD-LC-MS setups, in slightly different configurations. The technique’s efficacy is demonstrated through a case study on a cation exchange chromatography method assessing the charge variants of a bispecific antibody, isolating peak(s) of interest, followed by online sample processing, including reduction and enzymatic digestion, and subsequently mass spectrometry analysis. Results: The accuracy and reproducibility of both mD-LC-MS setups proposed in this study were successfully tested. Despite the complex peak patterns in the first dimension, the systems were equally effective in identifying and quantifying the underlying product species. This case study highlights the routine usability of mD-LC-MS technology for the characterization of (ultra) high-performance liquid chromatography (UHPLC) of therapeutic biomolecule. Conclusions: The demonstrated reliability and accuracy underscore the practicality of mD-LC-MS for routine use in biopharmaceutical analysis. Our detailed description of the mD-LC-MS systems and insights simplify access to this advanced technology for a broader scientific community, regardless of expertise level, and lower the entry barrier for its use in various research and industrial settings.